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Abstract 
Aim: Activation of neuropeptide Y1 receptors (NPYR1’s) by the peptide hormone, Peptide 
YY (PYY), evokes benefits on pancreatic beta-cells. However, rapid N-terminal enzymatic 
cleavage of PYY in the circulation dramatically diminishes NPYR1 specificity. The aim of the 
current study was to investigate antidiabetic efficacy of enzymatically stable PYY peptides. 
Materials and Methods: N-terminally stabilised, PYY(1-36) sequences from phylogenetically 
ancient fish, namely Amia calva (bowfin), Oncorhynchus mykiss (trout), Petromyzon marinus 
(sea lamprey) and Scaphirhynchus albus (sturgeon), were synthesised and both biological 
actions and antidiabetic therapeutic efficacy assessed.  
Results: All fish PYY(1-36) peptides were resistant to dipeptidyl peptidase-4 (DPP-4) 
degradation and inhibited glucose- and alanine-induced (P<0.05 to P<0.001) insulin secretion. 
In addition, PYY(1-36) peptides imparted significant (P<0.05 to P<0.001) beta-cell 
proliferative and anti-apoptotic benefits. Proliferative effects were almost entirely absent in 
beta-cells with CRISPR-Cas9 induced knockout of Npyr1. In contrast to human PYY(1-36), 
the piscine-derived peptides lacked appetite suppressive actions. Twice daily administration of 
sea lamprey PYY(1-36), the superior bioactive peptide, for 21-days significantly (P<0.05 to 
P<0.001) decreased fluid intake, non-fasting glucose and glucagon in streptozotocin (STZ)-
induced diabetic mice. In addition, glucose tolerance, insulin sensitivity, pancreatic insulin and 
glucagon content were significantly improved. Metabolic benefits were linked to positive 
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changes in pancreatic islet morphology, as a result of augmented (P<0.001) proliferation and 
decreased apoptosis of beta-cells. Sturgeon PYY(1-36) exerted similar but less impressive 
effects in STZ mice.  
Conclusion: The current observations reveal, for the first time, that PYY(1-36) peptide 
sequences from phylogenetically ancient fish replicate the pancreatic beta-cell benefits of 
human PYY(1-36) and possess clear potential for the treatment of type 2 diabetes.  
 
Keywords: Peptide YY (PYY); degradation; insulin secretion; beta-cell; appetite; bowfin; trout; 
sturgeon; lamprey  
 
Introduction  
Peptide Tyrosine Tyrosine (PYY), a gut-derived 36 amino acid residue peptide hormone, is 
released post-prandially from intestinal L-cells and imparts important effects on food intake 
and metabolism [2]. These biological actions are mediated through binding and interaction with 
neuropeptide Y receptors (NPYRs) [2].  PYY(1-36) is a full agonist for all human NPYR 
subtypes, namely NPY1, NPY2, NPY4 and NPY5 receptors [2,3]. However, rapidly after 
release into the circulation PYY(1-36) is degraded by the ubiquitous enzyme dipeptidyl 
peptidase-4 (DPP-4), to yield PYY(3-36) [4]. This N-terminal degradation dramatically alters 
the biological activity of PYY, since PYY(3-36) is a NPY2R-selective agonist, with negligible 
activity at other NPYRs [5]. Given knowledge of the appetite suppressive effects of 
hypothalamic NPYR2 activation [6], PYY(3-36) has been extensively studied as a potential 
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anti-obesity drug [7-9]. Despite this, PYY(3-36) based drugs have yet to be exploited clinically, 
likely due to adverse gastrointestinal side-effects following administration in humans [10].  
 A more exciting area of PYY research in recent times relates to beneficial effects of 
PYY(1-36) at the level of the endocrine pancreas [11]. The NPYR1 is abundantly expressed 
on pancreatic beta-cells [12], with local islet synthesis and secretion of PYY(1-36) also noted 
[13]. Indeed, there is a suggestion that the impressive endocrine pancreatic benefits following 
Roux-en-Y gastric bypass (RYGB) surgery are linked to altered PYY secretion and enhanced 
NPYR1 activity [14]. As such, confirmed pancreatic effects of NPYR1 activation include 
inhibition of glucose-stimulated insulin secretion (GSIS) to induce beta-cell rest, as well as 
promoting growth and survival of beta-cells [13,15]. Since both major forms of diabetes 
mellitus, type 1 (T1DM) and type 2 (T2DM), are associated with beta-cell loss and/or 
dysfunction [16,17], agents mimicking the action of PYY(1-36) on pancreatic beta-cells could 
possess distinct therapeutic usefulness. Consequently, N-terminally stabilised PYY(1-36) 
peptide analogues, resistant to DPP-4 degradation to maintain NPYR1 activity, are of particular 
interest. A recent study has employed available PYY/NPYR1 structure/function knowledge in 
an attempt to generate enzymatically stable, NPYR1 specific, PYY(1-36) sequences [18]. 
However, the bioactivity of these chemically engineered PYY(1-36) peptides was less 
impressive than anticipated [18]. Consequently, there is still an imperative need to develop 
stabilised PYY(1-36) peptides, with NPYR1 specificity, as a possible new and effective class 
of antidiabetic therapeutics. 
 The NPY family of peptides arose via successive duplications of an ancestral gene, to 
produce the distinct genes that encode for pancreatic polypeptide (PP), neuropeptide Y (NPY) 
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and PYY [19]. From evolutionary data, it has been established that the primary structure of 
PYY(1-36) is strongly conserved in fish [19]. Therefore, PYY(1-36) sequences from 
phylogenetically ancient fish may represent the most structurally ancient, highly conserved, 
PYY peptides in nature. For the present study, we sought to identify ancient fish PYY(1-36) 
sequences with inherent protection against DPP-4 activity, as naturally occurring NPYR1 
specific PYY molecules. Computational and structural analyses revealed Amia calva (bowfin), 
Oncorhynchus mykiss (trout), Petromyzon marinus (sea lamprey) and Scaphirhynchus albus 
(sturgeon) PYY(1-36) as the most credible options in this regard. Initial studies examined 
enzymatic stability of these piscine PYY(1-36) sequences to purified DPP-4. In addition, 
effects on pancreatic beta-cell function, growth and survival were assessed, alongside NPYR1 
and NPYR2 specificity. The impact of PYY(1-36) peptides on glucose homeostasis, insulin 
secretion and satiety were also investigated in vivo. Finally, we examined beneficial metabolic 
and related pancreatic architectural effects of twice-daily injection of the most promising 
piscine-derived peptides in streptozotocin (STZ)-induced diabetic mice. The data reveal, for 
the first time, that PYY(1-36) peptide sequences from phylogenetically ancient fish are 
metabolically stable and recapitulate in mammals the pancreatic beta-cell benefits of human 
PYY(1-36), with unmistakable therapeutic potential for type 2 diabetes. 
 
Materials and Methods  
Peptides  
All peptides were supplied by Synpeptide Ltd (Shanghai, China) in excess of 95% purity and 
characterised in-house by HPLC with MALDI-TOF (Table 1), as described previously [20].  
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Degradation by DPP-4  
PYY(1-36) peptides (50 µg) were incubated at 37oC on a plate-shaker in 50 mM 
triethanolamine/HCl (pH 7.8) with 0.05 U of purified DPP-4 (Sigma Aldrich) for 0 and 8 hours. 
Reactions were terminated by addition of 10 µl of 10% (v/v) trifluoroacetic acid/water. 
Reaction mixes were separated by RP-HPLC using a (250 x 4.6 mm) Phenomenex C-18 
analytical column, with absorbance monitored at 214 nm using a Thermoquest, SpectraSystem 
UV2000 detector. Defined HPLC peaks were collected and identified via MALDI-TOF MS on 
a PerSeptive Biosystems Voyager-DE Biospectrometer (Hertfordshire, UK), to corroborate 
peptide stability, as described previously [18]. 
 
In vitro insulin secretion  
In vitro effects of PYY(1-36) peptides on insulin secretion were determined using rodent 
BRIN-BD11 beta-cells. The characteristics of this cell line, including glucose-sensitivity and 
insulin secretory function, have been described in detail previously [21]. Cells were cultured 
in RPMI 1640 media (Gibco Life Technologies Ltd), supplemented with 10% v/v foetal bovine 
serum (Gibco), 1% v/v antibiotics (0.1 mg/ml streptomycin and 100 U/ml penicillin) at 37oC 
in 5% atmospheric CO2. For experimentation, cells were seeded into 24-well plates (Falcon 
Ltd) at a density of 150,000 cells per well. Following overnight attachment, media was 
aspirated and cells were pre-incubated in 1.1 mM glucose KRB buffer for 40 minutes. 
Following removal of pre-incubation buffer, 1 ml of KRB test solution, containing either 5.6 
or 16.7 mM glucose with PYY(1-36) test peptides (10-12 – 10-6 M) was added. In a second series 
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of experiments, insulin secretory effects of PYY(1-36) peptides were determined following 
incubation in the presence of alanine (10 mM) [18]. For all experiments, following a 20 min 
incubation period, supernatant was collected and stored at -20oC until determination of insulin 
concentrations by a fully characterised dextran coated charcoal radioimmunoassay [22].  
 
Beta-cell proliferation and apoptosis  
To assess the effects of PYY(1-36) peptides (10-8 and 10-6 M) on beta-cell proliferation and 
protection against apoptosis, rodent BRIN-BD11 and human 1.1B4 beta-cells [23] were used. 
Both hybrid cells lines were created using electrofusion technology of rodent or human islets 
and an appropriate immortal cell fusion partner [21,23]. Cells were seeded onto sterilised clear-
glass coverslips (16 mm diameter) and placed in 12-well plates (Falcon Ltd) at a density of 
40,000 cells per well and cultured for 18 h. Unsupplemented media, GLP-1 (10-8 and 10-6 M) 
and a cytokine cocktail mix (IL-1β (100 U/mL), IFNγ (20 U/mL), TNFα (200 U/mL)) were 
employed as controls, as appropriate. Cells were subsequently rinsed with PBS and fixed using 
4% paraformaldehyde. After antigen retrieval with sodium citrate buffer at 95oC for 20 min, 
blocking was performed using 2% BSA for 45 min. For proliferation studies, the coverslips 
were incubated at 37oC with rabbit anti-Ki-67 primary antibody (Abcam, ab15580), and then 
with Alexa Fluor® 488 secondary antibody. Coverslips were mounted onto polysine-coated 
microscope slides and mounted using a 50:50 Glycerol:PBS solution and stored at 4oC until 
required for analysis. To assess receptor selectivity, beta-cell proliferative effects of peptides 
were examined in an additional study using INS1 832/13 cells with CRISPR-Cas9 induced 
knockout (KO) of either the Npy1r or Npyr2. INS1 832/13 cells were chosen for these studies 
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based on their superior transfection efficiency and increased secretory responsiveness when 
compared to BRIN BD11 or 1.1B4 cells. Details on generation and characterisation of both 
KO cell lines is available within the supplementary material. To determine the ability of 
PYY(1-36) peptides to protect against cytokine-induced apoptosis, BRIN BD11 and 1.1B4 
cells were seeded, washed and fixed as above, with the exception that the media was 
supplemented with the cytokine mix. The coverslips were then incubated at 37oC with TUNEL 
reaction mix (Roche Diagnostics Ltd, UK) for 60 min, and mounted onto microscope slides, as 
above. All slides were viewed using a fluorescent microscope (Olympus System Microscope, 
model BX51; Southend-on-Sea, UK) and photographed by DP70 camera adapter system. 
Proliferation/TUNEL positive frequency was determined using the cell-counter function on 
ImageJ Software and expressed as % of total cells analysed, as described previously from our 
laboratory [13,18].  
 
Animals  
Acute animal studies were performed using adult male NIH Swiss TO mice (12 weeks of age, 
Envigo Ltd, UK). Longer-term studies to assess antidiabetic efficacy were conducted in male 
NIH Swiss TO mice (14 weeks of age), with diabetes induced by multiple low dose 
streptozotocin (STZ) injection (4 h fast, 50 mg/kg bw, i.p., in sodium citrate buffer, pH 4.5), 
for 5 consecutive days. Once diabetes was established, animals were matched for body weight 
and blood glucose and recruited onto the study. An additional group of mice (n=8) received 
saline instead of STZ injections. Mice were provided with standard rodent chow (10% fat, 30% 
protein and 60% carbohydrate; Trouw Nutrition, Northwich, UK) and drinking water ad 
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libitum. Mice were housed individually and kept in a temperature-controlled environment (22 
± 2oC), with a 12 hour light/dark cycle. Experiments were carried out in accordance with the 
UK Animal Scientific Procedures Act 1986.  
 
Acute in vivo effects  
Acute effects of PYY(1-36) peptides on food intake were tested in overnight (18 h) fasted mice. 
Mice were administered an intraperitoneal (i.p.) injection of saline vehicle (0.9% (w/v) NaCl) 
alone or in combination with test peptides (each at 25 nmol/kg bw) and cumulative food intake 
measured at regular intervals. Furthermore, effects of PYY(1-36) peptides on glucose 
homeostasis and insulin secretion were evaluated following i.p. injection of glucose alone (18 
mmol/kg bw) or in combination with test peptides (each at 25 nmol/kg bw) in overnight fasted 
mice.  
 
Sub-chronic in vivo effects  
Following recruitment into respective studies, diabetic NIH mice (n=8) received twice‐daily 
injections (09:00 and 17:00 h) of saline vehicle (0.9% (w/v) NaCl) or test peptides (each at 25  
nmol/kg bw) for 21 days. Cumulative energy and fluid intake, body weight, circulating glucose 
and plasma insulin were assessed at regular intervals. At the end of the treatment period, 
glucose tolerance (18 mmol/kg bw; i.p.; 18 h-fasted mice) and insulin sensitivity (25 U/kg 
bovine insulin; i.p.; non-fasted mice) tests were performed. Terminal analyses included 
extraction of pancreatic tissue with appropriate processing for measurement of hormone 
content following acid/ethanol protein extraction or determination of islet architecture, as 
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described previously [13]. In addition, co-staining of insulin (1:500; Abcam, ab6995) or 
glucagon (PCA2/4, 1:200; raised in-house) with Ki-67 (1:400; Abcam ab15580) and TUNEL 
reaction mixture (Roche Diagnostics Ltd, UK) was used to assess beta-cell proliferation and 
apoptosis. Following incubation with primary antibodies, appropriate fluorescent secondary 
antibodies were employed (Table 2). Slides were viewed under a FITC (488 nm) or TRITC 
filter (594 nm), as appropriate, using a fluorescent microscope (Olympus system microscope, 
model BX51) and photographed using a DP70 camera adapter system. Islet parameters were 
analysed using CellF image analysis software (Olympus Soft Imaging Solutions, GmbH).   
 
Biochemical analyses 
Blood samples were collected from the cut tip on the tail vein, of conscious mice, at times 
indicated in Figures 3-5. Blood glucose was measured immediately using a hand-held Ascencia 
Contour blood glucose meter (Bayer Healthcare, Newbury, Berkshire, UK). For plasma insulin, 
glucagon and C-reactive protein (CRP), blood was collected in chilled fluoride/heparin coated 
micro-centrifuge tubes (Sarstedt, Numbrecht, Germany) and centrifuged using a Beckman 
micro-centrifuge (Beckman Instruments, Galway, Ireland) for 10 minutes at 12,000 rpm. 
Plasma was separated and stored at -20oC, until determination of plasma insulin by 
radioimmunoassay [22] and glucagon or CRP by commercially available ELISA kits (EZGLU-
30K and RAB1121; respectively, Merck Millipore).  
 
Statistical analysis  
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Statistical analyses were performed using GraphPad PRISM software (Version 5.0). Values are 
expressed as mean ± S.E.M. Comparative analyses between groups were carried out using a 
One-way ANOVA with Bonferroni’s post hoc test or student's unpaired t-test, as appropriate. 
The difference between groups was considered significant if P<0.05. 
 
Results  
In vitro DPP-4 stability  
As expected, incubation of human PYY(1-36) with DPP-4 for 8 h resulted in generation of the 
N-terminally cleaved product, PYY(3-36) (Table 1). In contrast, the fish PYY(1-36) peptides, 
namely bowfin, trout, sturgeon and sea lamprey, were completely resistant to DPP-4 mediated 
degradation over the 8 h period (Table 1).  
 
Effects of fish PYY(1-36) peptides on insulin secretion from BRIN BD11 beta-cells  
Human PYY(1-36), and all related piscine-derived PYY(1-36) peptides, significantly (P<0.05 
to P<0.001) inhibited insulin secretion from BRIN BD11 cells at 5.6 mM glucose at 
concentrations of 10-10 M and above (Figure 1A). Interestingly, the PYY(1-36) sequences from 
phylogenetically ancient fish were more effective in this regard (P<0.05 to P<0.001) compared 
with human PYY(1-36) at 10-7 and 10-6 M (Figure 1A). Indeed, sea lamprey PYY(1-36) was 
significantly (P<0.05) more efficacious than human PYY(1-36) at 10-8 M (Figure 1A). In a 
similar fashion, all PYY(1-36) peptides had insulinostatic actions at 16.7 mM glucose, although 
only at concentrations of 10-7 M and above for human PYY(1-36), whereas all piscine-derived 
peptides were effective at 10-11 M (Figure 1B). Further to this, all PYY(1-36) peptides (10-7 
This article is protected by copyright. All rights reserved.
 
 
 
and 10-6 M), barring bowfin PYY(1-36) at 10-7 M, inhibited (P<0.05 – P<0.001) alanine-
evoked elevations of insulin secretion (Figure 1C).  
 
Effects of fish PYY(1-36) peptides on beta-cell proliferation and protection against 
cytokine-induced apoptosis  
GLP-1, PYY(1-36) and all fish PYY(1-36) peptides imparted significant (P<0.05 to P<0.001) 
protective effects against cytokine-induced apoptosis in both BRIN BD11 (Figure 2A) and 1.1 
B4 (Figure 2B) beta-cells. In terms of proliferative actions, both human GLP-1 and PYY(1-36) 
(10-8 and 10-6 M) significantly (P<0.01 to P<0.001) augmented BRIN BD11 and 1.1B4 beta-
cell proliferation (Figure 2C,D). The fish PYY(1-36) peptides also possessed similar 
significant (P<0.05 to P<0.001) beta-cell proliferative actions in both cell lines, with the 
exception of 10-8 M sturgeon PYY(1-36) in BRIN BD11 cells and 10-8 M trout PYY(1-36) in 
1.1B4 cells (Figure 2C,D). To probe which NPY receptor is involved in mediating actions of 
PYY(1-36) peptides, beta-cell proliferative effects were examined in INS1 832/13 cells with 
Npy1r or Npy2r KO introduced by CRISPR-Cas9 (Figure 2E). As expected from observations 
in BRIN BD11 and 1.1B4 cells, GLP-1 and all PYY(1-36) peptides (at either 10-6 or 10-8 M) 
effectively (P<0.05 to P<0.01) promoted beta-cell proliferation in INS1 832/13 cells (Figure 
2E). In Npy1r KO cells, all PYY(1-36) peptides were ineffective in terms of stimulating beta-
cell growth, with the exception of trout PYY(1-36) at 10-6 M (Figure 2E). All piscine PYY(1-
36) peptides imparted beta-cell proliferative actions in Npy2r KO cells at concentrations of 
either 10-8 or 10-6 M (Figure 2E).  
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Acute effects of fish PYY(1-36) peptides on food intake, glucose tolerance and insulin 
secretion in mice  
Intraperitoneal administration of 25 nmol/kg human PYY(1-36) to overnight fasted mice 
induced a significant reduction (P<0.05 to P<0.01) in food intake at 120 minutes post injection 
(Figure 3A). None of the piscine PYY(1-36) peptides had appetite suppressive actions over the 
observation period (Figure 3A). Indeed, bowfin PYY(1-36) significantly (P<0.05 to P<0.01) 
increased food intake when compared to saline control mice at several time points (Figure 4). 
Moreover, all fish PYY(1-36) peptides, barring sturgeon PYY(1-36), increased (P<0.05 to 
P<0.001) food intake when compared to human PYY(1-36) (Figure 3A). None of the PYY(1-
36) peptides had any effect on glucose homeostasis or insulin secretion when administered in 
combination with glucose to mice (Figure 3B-E).  
 
Sub-chronic effects of sea lamprey and sturgeon PYY(1-36) on body weight, food and 
fluid intake as well as circulating glucose, glucagon, insulin and CRP in STZ-induced 
diabetic mice  
Based on the above results, sea lamprey and sturgeon PYY(1-36) were selected to examine 
sub-chronic beneficial effects in STZ-induced diabetic mice. There was a progressive loss of 
body weight in all STZ diabetic mice over the 21-day treatment period (Figure 4A). This body 
weight reduction was significantly (P<0.05) countered by sea lamprey or sturgeon PYY(1-36) 
(Figure 4B). Cumulative food intake was increased (P<0.01 to P<0.001) in STZ mice on days 
18 and 21, and in sturgeon PYY(1-36) mice (P<0.05) on day 21, when compared to lean 
controls (Figure 4C). Fluid intake was substantially (P<0.05 to P<0.001) increased in saline 
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and sturgeon PYY(1-36) treated STZ mice, but significantly (P<0.05 to P<0.01) reduced in sea 
lamprey PYY(1-36) treated mice from day 9 onwards (Figure 4D). As would be expected, 
circulating glucose levels steadily increased (P<0.01 to P<0.001) in control diabetic STZ mice, 
but were significantly (P<0.05 to P<0.001) decreased by sea lamprey PYY(1-36) from day 16 
onwards (Figure 4E). Corresponding non-fasting plasma insulin concentrations were elevated 
(P<0.01 to P<0.001) in sea lamprey treated mice from day 13 when compared to diabetic 
control mice (Figure 4F). Similar observations on circulating insulin were made in mice treated 
with sturgeon PYY(1-36), with the exception of day 21, where insulin concentrations were 
similar to saline control levels (Figure 4F). Circulating glucagon was significantly (P<0.01) 
reduced in sea lamprey and sturgeon PYY(1-36) treated STZ mice on day 21, with levels 
similar to those observed in lean control mice (Figure 4G). CRP concentrations were not 
different between groups of diabetic mice (data not shown).  
 
Sub-chronic effects of sea lamprey and sturgeon PYY(1-36) on glucose tolerance, 
peripheral insulin sensitivity as well as pancreatic insulin and glucagon content in STZ-
induced diabetic mice  
During glucose tolerance tests on day 21, plasma glucose levels were significantly (P<0.05) 
reduced at 15, 30 and 90 min post‐injection in  mice treated twice daily with sea lamprey 
PYY(1-36) when compared with STZ diabetic controls (Figure 5A). Subsequent AUC analysis 
confirmed a significantly (P<0.01) reduced glycaemic excursion with sea lamprey PYY(1-36) 
(Figure 5A). Sturgeon PYY(1-36) treatment had no impact on individual or overall glucose 
levels following a glucose challenge on day 21 (Figure 5A). Corresponding glucose-induced 
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plasma insulin concentrations were elevated (P<0.05) at 30 min post glucose injection in both 
sea lamprey and sturgeon PYY(1-36) treated mice when compared to STZ controls (Figure 
5B). However, only sea lamprey PYY(1-36) treatment increased (P<0.05) the net insulin 
secretory response compared to diabetic control mice, but this was still reduced (P<0.001) 
when compared to lean controls (Figure 5B). The overall glucose-lowering action of exogenous 
insulin injection was significantly (P<0.05) enhanced in sea lamprey, but not sturgeon, PYY(1-
36) treated mice when compared to STZ‐induced  diabetic controls (Figure 5C). Pancreatic 
insulin content was significantly elevated in both sea lamprey (P<0.001) and sturgeon (P<0.05) 
treated mice when compared to STZ diabetic controls (Figure 5D). Corresponding pancreatic 
glucagon content was elevated (P<0.001) in STZ mice, but significantly (P<0.001) reduced by 
sea lamprey PYY(1-36) treatment (Figure 5E).   
   
Sub-chronic effects of sea lamprey and sturgeon PYY(1-36) on pancreatic morphology in 
STZ-induced diabetic mice  
Clear abnormalities of pancreatic morphology were evident in STZ diabetic mice including 
appearance of more centrally located glucagon-stained cells (Figure 6A-D). Quantitative 
evaluation confirmed this in saline (P<0.001) and sturgeon PYY(1-36) (P<0.05) treated STZ 
mice, whereas sea lamprey PYY(1-36) treated mice had reduced (P<0.001) appearance of 
centrally located alpha-cells, and similar to lean control mice (Figure 6E). The number of 
pancreatic islets was not significantly different in sea lamprey PYY(1-36) treated STZ and lean 
control mice, whereas STZ and sturgeon PYY(1-36) treated mice had reduced (P<0.001) islet 
numbers (Figure 6F). Interestingly, overall islet area was decreased (P<0.01) with sea lamprey 
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PYY(1-36) treatment when compared to lean controls (Figure 6G), which could be related to 
the decreased (P<0.001) percentage of alpha cell area in these mice (Figure 6H). Percentage 
beta-cell area was decreased (P<0.001) in all STZ mice compared to lean controls, but elevated 
(P<0.01) in sea lamprey PYY(1-36) mice when compared to STZ diabetic controls (Figure 6I). 
In keeping with this, proliferating and apoptotic beta-cells were significantly (P<0.001) 
increased and decreased, respectively, in sea lamprey PYY(1-36) treated mice when compared 
to diabetic controls, and not significantly different from lean mice (Figure 6J,K). Whilst the 
percentage of proliferating alpha-cells was not different between the various groups of mice 
(Figure 6L), sea lamprey PYY(1-36) treatment significantly (P<0.05) reduced alpha-cell 
apoptosis although levels were still elevated (P<0.01) when compared to lean control mice 
(Figure 6M). Sturgeon PYY(1-36) treatment had no effect on alpha- and beta-cell area, or the 
number of proliferating and apoptotic alpha- or beta-cells when compared to STZ controls 
(Figure 6H-M). Representative images from each treatment group showing insulin and 
glucagon positive islet cells, co-stained with Ki-67 or TUNEL, are provided in the 
supplementary material. 
 
Discussion  
The difficulties in developing an enzymatically stable, NPYR1 specific, PYY(1-36) analogue 
based on current structure/function knowledge for PYY(1-36) have recently been highlighted 
[18]. In brief, a PYY(1-36) peptide analogue adopting the key characteristics known to enhance 
NPYR1 interaction, namely substitution of Val31 for Leu31 and Gln34 for Pro34 [24], exhibited 
noticeably diminished bioactivity at the level of the pancreatic beta cell [18]. To date, the only 
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other description of a stable PYY analogue with some reported NPYR1 activity, named X-
PYY [25], is based on the sequence of PYY(3-36) that is considered to be a highly specific 
NPYR2 agonist [5].   
We have previously successfully exploited highly conserved amino acid sequences 
from phylogenetically ancient fish in the search for naturally occurring, enzymatically 
stabilised, peptide hormone receptor agonists; including glucagon and GLP-1 [26-29]. The 
primary structures of bowfin, sea lamprey, sturgeon and trout PYY(1-36) peptides are depicted 
in Table 1, and compared to human PYY(1-36) and NPY, since these are established NPYR1 
agonists [30]. It is apparent that the entire C-terminal segment, from residues 23-36, of all fish 
PYY(1-36) peptide sequences is highly conserved between human PYY and NPY. This is of 
considerable importance given that the C-terminus of the NPY family of peptides is 
fundamentally important for NPYR1 binding [31]. Although all piscine PYY(1-36) peptides 
have insertion of an Ile residue at positions 28 and 31, which is different to human PYY(1-36), 
such changes directly correspond to the human NPY sequence. More remarkably, Ile28 and Ile31 
have been shown to be important for conservation of peptide helical structure and NPYR1 
interaction [32]. A similar Ala23 for Ser23 substitution in the piscine sequences has also been 
noted to stabilise helical structure and enhance NPYR1 binding capacity [33-35]. The Val24 for 
Leu24 substitution in sea lamprey PYY(1-36) represents removal of a single methylene group, 
and likely to have minor implications on overall peptide conformation [36].  
Moreover, when peptide sequences are studied in more detail, for bowfin PYY(1-36) 
the only non-conserved residue when compared to the sequences of human NPY and PYY is 
Pro3. For trout PYY(1-36), in addition to the Pro3 change, there are also Lys19 for Arg19 and 
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Thr22 for Ser22 substitutions, representing replacements with amino acids that possess the same 
charge or polarity, respectively. The additional amino acid substitutions within sea lamprey 
and sturgeon PYY(1-36) provide less obvious intimations to structure/function, perhaps 
barring the similar negative charge of Asp10 and Glu10 in sturgeon and human PYY, 
respectively. Further important structure/function knowledge relating to the NPY family of 
peptides concerns the characteristic ‘PP-fold’ conformation [37], responsible for bringing the 
N- and the C-terminal ends of the peptide in close contact to be recognised by the NPYR1 [38]. 
This PP-fold is characterised by the poly-proline N-terminal segment, Pro2-Pro5-Pro8, 
stabilised by a Pro residue situated either at position 13 or 14 and folded back on a long 
amphipathic α-helix interacting with Tyr20 and Tyr27 [38]. Notably these residues are all 
conserved across the four piscine PYY(1-36) sequences. Taken together, the fundamental 
structural characteristics necessary for specific human NPYR1 binding and activation are 
present within bowfin, sea lamprey, sturgeon and trout PYY(1-36) peptide sequences. 
In full agreement, the present study has demonstrated that PYY(1-36) peptides from 
these phylogenetically ancient fish possess similar bioactivity as human PYY(1-36) in the 
current mammalian test systems. All PYY(1-36) peptides inhibited both glucose- and alanine-
induced insulin secretion, whilst encouraging beta-cell growth and protecting against apoptosis 
[13,18]. There were some slight differences in potency and efficacy, possibly indicating 
enhanced NPYR1 specificity of the piscine-derived peptides. In relation to this, human PYY(1-
36) is subject to DPP-4 mediated, N-terminal dipeptide cleavage, generating a PYY(3-36) 
metabolite with dramatically reduced NPYR1 selectivity [4]. It has already been established 
that substitution with a proline residue at position three in human PYY(1-36) renders the 
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peptide resistant to DPP-4 [18]. This is similar to observations with other DPP-4 liable peptide 
hormones, such as GIP and GLP-1 [39,40]. All piscine PYY(1-36) sequences contain a 
naturally occurring Pro3 residue, and as expected, were enzymatically stable. To examine 
NPYR1 specificity in more detail, beta-cell proliferative effects of the PYY(1-36) peptides 
were examined in INS1 832/13 cells [41], with either Npy1r or Npy2r KO. In Npy1r KO cells, 
all PYY(1-36) peptides were ineffective in terms of stimulating beta-cell growth, with the 
exception of trout PYY(1-36) at the highest concentration tested, whereas all PYY(1-36) 
peptides displayed bioactivity in Npy2r KO cells. Therefore, the biological actions of trout 
PYY(1-36) may not be confined solely to interaction with NPYR1, unlike the other piscine 
peptides. Dual receptor activation properties of phylogenetically ancient fish peptides has been 
documented previously [26,29], and this could be of importance here.  
In keeping with preserved NPYR1 activity of the fish derived peptides, appetite 
stimulatory effects of all peptides, barring sturgeon PYY(1-36), was observed when compared 
to human PYY(1-36). Notably, the increase in food intake by the piscine-derived PYY(1-36) 
peptides was only relative to human PYY(1-36). As such, none of the fish PYY(1-36) peptides 
increased food intake above saline control at the end of the observation period. Metabolism of 
human PYY(1-36) to PYY(3-36) in vivo results in appetite suppressive effects linked to 
NPYR2 activation [1,42], which would not occur with the piscine peptides. In agreement with 
limited acute insulinotropic or glucose homeostatic actions of PYY(1-36) [18], none of the 
peptides influenced glucose clearance or circulating plasma insulin when injected concurrently 
with glucose to mice. Based on these in vitro and in vivo studies, sturgeon and sea lamprey 
PYY(1-36) were selected to examine effects of sub-chronic twice daily administration in 
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insulin-deficient STZ-diabetic mice. As such, sturgeon, and especially sea lamprey, PYY(1-
36) partially corrected the characteristic weight loss, as well as increased water and food intake, 
in insulin-deficient STZ-diabetic mice [43]. The exact explanation as to why sea lamprey was 
more effective than sturgeon PYY is not obvious, especially given their similar in vitro 
biological action profiles, but could be related to differences in receptor binding kinetics or 
peptide half-lives, that requires further detailed study. However, benefits of the peptides were 
associated with improved glycaemic control, glucose tolerance, insulin sensitivity and, 
importantly, elevated plasma and pancreatic insulin concentrations with reduced plasma and 
pancreatic glucagon in sea lamprey treated mice. Interestingly, PYY peptides are not 
considered to directly modulate glucagon secretion, suggesting indirect effects on alpha-cells 
via surrounding beta- or delta-cells [44]. However, the ability of sea lamprey PYY to restore 
both disturbed insulin and glucagon levels in diabetes is of significant clinical relevance. Thus, 
acute administration of NPYR1 specific peptides is associated with insulinostatic actions and 
beta-cell rest [13], whereas prolonged activation of beta-cell NPYR1’s promotes cell growth 
and survival, leading to significant elevations in basal and glucose-stimulated insulin 
concentrations [15]. Plasma CRP levels were unchanged indicating lack of adverse 
inflammatory responses to fish peptides.  
Consistent with metabolic benefits in STZ mice, beta-cell proliferation was enhanced 
and apoptosis decreased, by sea lamprey PYY(1-36) treatment. Thus, beta-cell area was 
increased, despite a marginal reduction overall islet area. Such observations directly correlate 
with knowledge that the notable pancreatic benefits of RYGB surgery are strongly linked to 
NPYR1 activation [14], alongside the recognised beta-cell pro-survival effects of PYY 
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peptides [18]. Moreover, selective KO of PYY expressing cells in mice results in 
hyperglycaemia, as a direct result of increased beta-cell destruction [25]. In addition, STZ-
induced insulin deficiency has been shown to decrease islet PYY expression [13]. Interestingly, 
the characteristic infiltration of glucagon positively stained central islet cells induced by STZ 
injection in mice [45] was reversed by sea lamprey PYY(1-36) treatment. Indeed, apoptotic 
rate of pancreatic alpha-cells was decreased by sea lamprey PYY(1-36) and proliferation 
unchanged, yet alpha-cell area and pancreatic glucagon content declined, implying strong 
likelihood of lineage transition of these cells. Given that PYY has an established role in early 
pancreatic islet cell development in utero [46], positive effects of sea lamprey PYY(1-36) on 
pancreatic islet cell plasticity and lineage reprograming would seem credible, but requires 
further detailed study.  
 In conclusion, the present study has demonstrated that PYY(1-36) peptide sequences 
from phylogenetically ancient fish represent enzymatically stable, human NPYR1 modulators. 
The highly beneficial beta-cell effects of chronic NPYR1 activation [15] was exemplified by 
sea lamprey PYY(1-36) treatment in STZ-induced insulin deficient mice, and importantly 
lacked any proinflammatory effects. Further studies are required to assess the time-course of 
these effects and relative contribution of beta-cell regeneration and beta-cell 
protection/recovery (both stimulated by PYY) to the final improved beta-cell mass and glucose 
response in the mice. However, notable improvements in islet morphology and insulin 
secretion induced by sea lamprey PYY(1-36) represents the first credible evidence that stable 
peptide analogues acting at NPYR1 can offer a novel and effective treatment option for 
diabetes. 
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Table 1. Amino acid sequences, expected and calculated masses as well as purity and DPP-4 stability for NPY and PYY(1-36) peptides 
 
 
Amino acids in bold text are conserved in human PYY(1-36). Amino acids in italic underlined text correspond to human NPY(1-36). Peptide 
masses were calculated using MALDI-TOF MS on a PerSeptive Biosystems Voyager-DE Biospectrometer. Peptide purity was assessed by HPLC 
and analysis of AUC data. For DPP-4 degradation, peptides (50 µg) were incubated at 37oC in 50 mM triethanolamine/HCl with DPP-4 (0.05 U) 
for 0 and 8 hours. Defined HPLC peaks were collected and identified via MALDI-TOF MS on a PerSeptive Biosystems Voyager-DE 
Biospectrometer. ND, not determined. 
 
Peptide Amino Acid Sequence Sequence homology (%) 
Expected 
Mass (Da) 
Calculated 
Mass (Da) 
Peptide 
purity 
% DPP-4 
degradation 
at 8 h 
Human NPY(1-36) Y-P-S-K-P-D-N-P-G-E-D-A-P-A-E-D-M-A-R-Y-Y-S-A-L-R-H-Y-I-N-L-I-R-Q-R-Y- NH2 - 4271.7 ND ND ND 
Human PYY(1-36) Y-P-I-K-P-E-A-P-G-E-D-A-S-P-E-E-L-N-R-Y-Y-A-S-L-R-H-Y-L-N-L-V-T-R-Q-R-Y- NH2 - 4309.8 4309.7 96.8 72.5 
Bowfin PYY(1-36) Y-P-P-K-P-E-N-P-G-E-D-A-P-P-E-E-L-A-R-Y-Y-S-A-L-R-H-Y-I-N-L-I-T-R-Q-R-Y - NH2 77.8 4317.8 4317.5 98.3 0 
Trout PYY(1-36) Y-P-P-K-P-E-N-P-G-E-D-A-P-P-E-E-L-A-K-Y-Y-T-A-L-R-H-Y-I-N-L-I-T-R-Q-R-Y - NH2 75.0 4303.9 4303.6 95.9 0 
Sturgeon  
PYY(1-36)  
F-P-P-K-P-E-H-P-G-D-D-A-P-A-E-D-V-V-K-
Y-Y-T-A-L-R-H-Y-I-N-L-I-T-R-Q-R-Y- NH2 61.1 4270.8 4270.4 96.2 0 
Sea Lamprey 
PYY(1-36)  
M-P-P-K-P-D-N-P-S-P-D-A-S-P-E-E-L-S-K-
Y-M-L-A-V-R-N-Y-I-N-L-I-T-R-Q-R-Y- NH2 61.1 4285.9 4284.2 98.5 0 
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Table 2. Target, host and source of primary and secondary antibodies employed for 
immunoflourescent islet histology and immunocytochemistry studies 
Primary antibodies 
Target Host Dilution Source 
Insulin Mouse 1:500 Abcam, ab6995 
Glucagon Guinea pig 1:200 Raised in-house, PCA2/4 
Ki-67 Rabbit 1:400 Abcam, ab15580 
Secondary antibodies 
Target Host Reactivity Dilution Fluorescent dye and source 
IgG Goat Mouse 1:400 Alexa Fluor® 594, Invitrogen, UK 
IgG Goat Guinea pig 1:400 Alexa Fluor® 488, Invitrogen, UK 
IgG Goat Guinea pig 1:400 Alexa Fluor® 594, Invitrogen, UK 
IgG Goat Rabbit 1:400 Alexa Fluor® 488, Invitrogen, UK 
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Figure legends 
Figure 1. Effects of PYY(1-36) peptides on insulin release from rodent BRIN-BD11 beta-
cells. BRIN BD11 cells were incubated with (A) 5.6, (B) 16.7 mM glucose or (C) 16.7 mM 
glucose supplemented with alanine (10 mM) and the effects of PYY peptides (10-6 – 10-12 M) 
on insulin secretion determined. Values are mean ± SEM (n=8). *P<0.05, **P<0.01, 
***P<0.001 compared to respective glucose control. ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared 
to (A) human PYY(1-36) or (C) 16.7 mM glucose plus 10 mM alanine.  
 
Figure 2. Effects of PYY(1-36) peptides on (A,B) protection against cytokine-induced 
apoptosis and (C-E) beta-cell proliferation. (A) BRIN-BD11 and (B) 1.1 B4 beta-cells were 
cultured (16 h) with PYY peptides or GLP-1 (10-8 and 10-6 M) in the presence of a cytokine 
cocktail and apoptosis detected using the TUNEL assay. (C) BRIN-BD11, (D) 1.1B4 and (E) 
INS1 832/13, as well as Npy1r or Npy2r KO INS1 832/13, beta-cells were cultured (16 h) with 
PYY peptides or GLP-1 (10-8 and 10-6 M) and proliferation assessed by Ki-67 staining. All 
values are mean ± SEM (n=3). (A,B) *P<0.05, **P<0.01, ***P<0.001 compared to cytokine-
cocktail. ΔΔP<0.01, ΔΔΔP<0.001 compared to RPMI media control. (C-E) *P<0.05, **P<0.01, 
***P<0.001 compared to RPMI media control. ΔP<0.05, ΔΔΔP<0.001 compared to unaltered 
INS1 832/13 wild-type cells at each condition. Representative images for each treatment are 
provided in the supplementary data.  
 
Figure 3. Effects of PYY(1-36) peptides on (A) food intake and (B) glucose tolerance and 
insulin secretion in overnight fasted mice. (A) Cumulative food intake was assessed after i.p. 
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administration of saline vehicle (0.9% NaCl) or in combination with PYY(1-36) peptides (25 
nmol/kg bw). (B) Blood glucose and (C) plasma insulin levels were assessed immediately prior 
to, and at regular intervals subsequent to, i.p. injection of PYY(1-36) peptides (each at 25 
nmol/kg bw dose) in combination with glucose (18 mmol/kg bw). Respective areas under the 
curve are shown in the insets. All values are mean ± SEM (n=6). *P<0.05, **P<0.01 compared 
to saline control. ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to human PYY(1-36). 
 
Figure 4. Effects of sea lamprey and sturgeon PYY(1-36) on (A) body weight, (B) % body 
weight reduction, (C) food and (D) fluid intake, non-fasting (E) blood glucose as well as 
plasma (F) insulin and (G) glucagon in STZ-induced diabetic mice. (A,C-F) Parameters 
were measured at regular intervals for 3 days before and 21 days during treatment with twice-
daily injection of sea lamprey and sturgeon PYY(1-36) (both peptides at 25 nmol/kg bw) in 
STZ-induced diabetic mice. (B,G) Parameters were measured on day 21. All values are 
expressed as mean ± SEM for 6 mice. *P<0.05, **P<0.01, ***P<0.001 compared with STZ 
diabetic control mice. ΔP<0.05, ΔΔP<0.01 and ΔΔΔP<0.001 compared with lean control mice.  
 
Figure 5. Effects of sea lamprey and sturgeon PYY(1-36) on (A,B) glucose tolerance, (C) 
peripheral insulin sensitivity as well as pancreatic (D) insulin and (E) glucagon content in 
STZ-induced diabetic mice. Parameters were measured at after 21 days during treatment with 
twice-daily injection of sea lamprey and sturgeon PYY(1-36) (both peptides at 25 nmol/kg bw) 
in STZ-induced diabetic mice. (A) Blood glucose and (B) plasma insulin were measured prior 
to and after i.p. administration of glucose alone (18 mmol/kg) at t = 0 min. (C) Blood glucose 
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was measured after i.p. administration of insulin (25 U/kg bw) at t = 0 min. (A-C) AUC data is 
shown in insets. (D,E) Pancreatic insulin and glucagon content was measured by RIA or 
ELISA, respectively, following acid-ethanol extraction. All values are expressed as 
mean ± SEM for 6 mice. *P<0.05, **P<0.01, ***P<0.001 compared with STZ diabetic control 
mice. 
 
Figure 6. Effects of sea lamprey and sturgeon PYY(1-36) on pancreatic morphology in 
STZ-induced diabetic mice. Parameters were measured after 21 days during treatment with 
twice-daily injection of sea lamprey and sturgeon PYY(1-36) (both peptides at 25 nmol/kg bw) 
in STZ-induced diabetic mice. (A-E) Representative images of islets showing insulin (red) and 
glucagon (green) immunoreactivity from each treatment group. (F) % centrally located alpha-
cells, (G) numbers of islets/mm2, (H) total islet area, percentage (I) alpha- and (J) beta-cell area 
as well as proliferating (K,M) and apoptotic (L,O) alpha- or beta-cells, as appropriate. All 
values are expressed as mean ± SEM for 6 mice. *P<0.05, **P<0.01, ***P<0.001 compared 
with STZ diabetic control mice. ΔP<0.05, ΔΔP<0.01 and ΔΔΔP<0.001 compared with lean control 
mice. Representative images of insulin and glucagon positive cells, co-stained with Ki-67 or 
TUNEL, for each treatment group are provided in the supplementary data.  
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